Denmark: Hemab closes US$135m Series B financing to support growth through 2025

Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has closed an oversubscribed US$135m Series B financing. Access Biotechnology led the round, with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well as all current investors Novo Holdings,…

You must be a HMI Subscriber to view this content.

Subscribe Now »